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October 20, 1977 Abstract This compound also has a potent depleting activity on brain and heart noradrenaline in rats (1). In biochemical investigations of 250059-S, we found that it caused depletion of liver glycogen without elevation of blood glucose. The present study was undertaken to clarify the action mechanism on carbohydrate metabolism.
MATERIALS AND METHODS

General
Male Wistar rats weighing about 150 g were used throughout this study except for the experiments on adrenaline release. The animals were sacrificed by exsangination. About 3 nil of blood was collected in heparinized glassware and 0.1 ml of the blood was rapidly diluted with 1.9 ml of distilled water for glucose determination. Blood glucose was de termined by the method of Hoffman (2) KOH was performed as rapidly as possible. Adrenal catecholamines were extracted in acid-butanol, transferred to the aqueous phase by shaking with n-heptane and water, absorbed on alumina at pH 7.2 and eluted with 0.06 N HCl. These procedures were done according to the method of Chang (7) with slight modification. Catecholamine contents in the eluate were determined by the method of Anton and Sayre (8). Adrenal demedullation was performed under pentobarbital anesthesia. The adrenals were exposed through a lumbar approach, the adrenal cortex was incised and the medulla extruded by gentle squeezing of the gland with forceps. The animals were treated with penicillin and given food and tap water ad libitum until used for experimentation about 30 days later.
Experiments for adrenaline release
Male Sprague-Dawley rats weighing 400 to 600 g were used. 250059-S was injected s.c. 45 min prior to the onset of withdrawal of adrenal-venous blood. The animals were anesthetized by ether inhalation 20 min after drug administration. A cannula was inserted in the saphenous vein for infusion of fluids. The abdomen was opened by a horizontal incision and the animals was heparinized. The left renal vein was ligated at both terminals and cannulated for collection of adrenal-venous blood. The abdomen was closed after coupling the two cannulas. During collection of adrenal-venous blood, Ringer's solution containing 0.1 % of glucose was infused at about 4 ml per min. Adrenaline content in the blood plasma was determined fluorimetrically. In splanchnicotomy, the left greater splanchnic nerve was incised near the diaphragm about 20 min prior to the onset of blood collection. The details have been described elsewhere (9).
Chemicals 250059-S was used as a suspension in 2.5% gum arabic. DL-Propranolol hydro chloride (Sigma) was used as 0.9 % saline solutions.
Statistical analysis
The significance of the difference between the means of the response was evaluated by Student's t-test.
RESULTS
Effect on blood glucose and liver glycogen
Changes in blood glucose and liver glycogen after s.c. injection of 250059-S are shown in Fig. 1 . 250059-S caused a marked depletion of liver glycogen, though there was no elevation in blood glucose. 250059-S-induced depletion activity of liver glycogen was not completely blocked by adrenal demedullation (Table 1) , although it completely vanished with pretreatment with 10 mg/kg of propranolol, which also inhibited the 250059-S-induced depletion of muscle glycogen ( Effect on adrenaline release Table 3 demonstrates the effect of 250059-S on adrenal levels of catecholamines. Ad renaline content was markedly depleted 2 hr after injection of 50 mg/kg, while the nor adrenaline content was not. Figure 2 illustrates the effect of 250059-S on adrenaline secretion from the left adrenal with the animal under ether anesthesia. Marked increase of adrenaline liberation was detected for a 15-min period from 45 min to 60 min after injection of 25 mg/kg or more of 250059-S. This hypersecretion of adrenaline was largely prevented by splanch nicotomy (Table 4) . 
Effect on adrenaline-hyperglycemia
The effect of pretreatment with 250059-S on the hyperglycemic action of adrenaline is shown in Table 5 . Pretreatment with 250059-S prevented the elevation of blood glucose caused by i.p. injection of 0.1 mg/ kg of adrenaline in a dose-related manner.
Effect on plasma level of insulin
The effect of 250059-S on plasma insulin level is shown in Table 6 . Plasma insulin level was elevated to twice the control level at 1 hr after s.c. injection of 10 mg/kg of 250059-S and was slightly lowered from this level at 2 hr. A similar change was found after a dosage of 25 mg/kg.
DISCUSSION
In these experiments, the marked decrease of adrenaline content in the adrenal glands after injection of 250059-S suggests hypersecretion of adrenaline. Indeed, a large increase of adrenaline release from the adrenals caused by 250059-S was detected with the animals under ether anesthesia. The rate of adrenaline secretion after 25 mg/kg or more of a s.c.
administration of 250059-S was almost equal that after 120 mg/kg i.p. injection of morphine hydrochloride, 10 mg/kg i.v. injection of histamine dihydrochloride or electrical stimulation of the splanchnic nerve (10, 11); this level is thought to be the maximum rate in rats. Ad renaline hypersecretion caused by 250059-S was largely prevented by splanchnicotomy.
This indicates that the site of action for adrenaline secretion of this compound is mainly in the central nervous system.
Adrenaline hyperglycemia is well known, and although an elevation of blood glucose is expected in response to hypersecretion of adrenaline caused by 250059-S, such is not the case. This contradictory finding can be explained by the blocking action of this compound on adrenaline hyperglycemia. A similar blockade occurs with dehydroergotamine (12, 13), but not phenotolamine (13): both are a-blockers. Takeda et al. of our laboratory found in their experiments with isolated thoracic artery and isolated vas deferens of guinea pig that 250059-S is a strong a-blocker (personal communication).
Here also 250059-S is similar to dehydroergotamine. 250059-S elevated the plasma insulin level, and this effect probably played a role in the inhibiting action of 250059-S on adrenaline hyperglycemia. As adrenaline has a marked glycogenolitic action, the 250059-S-induced hypersecretion of adrenaline probably plays a main role in the depletion of liver glycogen caused by this compound. Liver glycogen decreased significantly at doses over 5 mg/kg, although the increase of adrenaline secretion at doses of 10 mg/kg or less was small. Such a slight increase in adrenaline release could decrease liver glycogen, since under similar conditions, a slight but not statistically significant increase in adrenaline secretion caused by an antipyretic analgesic can markedly elevate blood glucose in rats (14).
Adrenal demedullation did not cause complete blockage of 250059-S-induced depletion of liver glycogen. Shimazu et al. (15, 16) showed that electrical stimulation of the splanchnic nerve increases glycogenolysis in rabbit liver, and the effect is not eliminated by adrenalectomy.
The observation that 250059-S strongly stimulated the splanchnic nerves suggests that peripheral catecholamines liberated by 250059-S play a role in the depleting of liver glycogen by this compound.
In our experiments, 250059-S-induced depletion of liver glycogen was inhibited by pretreatment with propranolol. This suggests that the action of 250059-S on liver glycogen is mediated by 8-receptors.
Kennedy and Ellis (17) showed that adrenaline-induced glycogenolysis in rat liver is inhibited by phentolamine, but not by dichloroisoproterenol. Recently, Hutson et al. (18) showed that the effect of adrenaline on carbohydrate metabolism in rat liver parenchymal cells is mediated predominantly by a-receptors and activation of Q-adrenergic receptors by adrenaline leads to accumulation of cyclic AMP, which is associated with minimal activation of phosphorylase or inactivation of glycogen synthase.
These observations are in contrast to our speculation. Sherline et al. (19) suggested from their in vitro experiments with isolated perfused rat liver that there are two mechanisms by which catecholamines can activate glycogen phosphorylase. One is through a (3-receptor mediated rise in cyclic AMP, and the other, a cyclic AMP-independent mechanism mediated by a-receptors. In the case of 250059-S, continued hypersecretion of catecholamines occurred under an a-receptor blockade by 250059-S itself, thus revealing a (3-receptor mediated glycogenolytic effect of catecholamines. However, other mechanisms such as 250059-S acting directly on the liver for the glycogenolytic action of this compound cannot be excluded.
Propranolol also blocked the depletion of muscle glycogen caused by 250059-S making it increase to slightly over the control level. Under our experimental conditions, propranolol acted similarly on the effect of adrenaline on muscle glycogen (unpublished observation).
These observations show that 250059-S causes depletion of muscle glycogen through ad renaline hypersecretion. 
